Skip to main content
Back
LFTSF logo

LifeTech Scientific Corporation

Data quality: 100%
Overbought
LFTSF
OTC Healthcare Medical - Devices
$0.23
$0.00 (0.00%)
Mkt Cap: 1.03B
Day Range
$0.23 $0.23
52-Week Range
$0.23 $0.23
Volume
100
50D / 200D Avg
$0.23 / $0.23
Prev Close
$0.23

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 4.6 0.4
P/B 0.3 2.9
ROE % 6.5 3.7
Net Margin % 17.1 3.9
Rev Growth 5Y % 19.4 10.0
D/E 0.0 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $0.11
$0.11 – $0.11
 1.7 B 1
FY2026 $0.08
$0.08 – $0.08
 1.5 B 1

Key Takeaways

Revenue grew 19.36% annually over 5 years — strong growth
Earnings declined -15.52% over the past year
Net margin of 17.06% shows strong profitability
Debt/Equity of 0.00 — conservative balance sheet
Generating 38.46M in free cash flow
P/E of 4.62 — trading at a low valuation

Growth

Revenue Growth (5Y)
19.36%
Revenue (1Y)2.88%
Earnings (1Y)-15.52%
FCF Growth (3Y)-14.69%

Quality

Return on Equity
6.48%
ROIC3.99%
Net Margin17.06%
Op. Margin14.29%

Safety

Debt / Equity
0.00
Current Ratio2.86
Interest Coverage98.59

Valuation

P/E Ratio
4.62
P/B Ratio0.29
EV/EBITDA1.97
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 2.88% Revenue Growth (3Y) 9.00%
Earnings Growth (1Y) -15.52% Earnings Growth (3Y) -17.32%
Revenue Growth (5Y) 19.36% Earnings Growth (5Y) 0.72%
Profitability
Revenue (TTM) 1.30B Net Income (TTM) 222.39M
ROE 6.48% ROA 4.54%
Gross Margin 75.28% Operating Margin 14.29%
Net Margin 17.06% Free Cash Flow (TTM) 38.46M
ROIC 3.99% FCF Growth (3Y) -14.69%
Safety
Debt / Equity 0.00 Current Ratio 2.86
Interest Coverage 98.59 Dividend Yield 0.00%
Valuation
P/E Ratio 4.62 P/B Ratio 0.29
P/S Ratio 0.79 PEG Ratio -2.48
EV/EBITDA 1.97 Dividend Yield 0.00%
Market Cap 1.03B Enterprise Value 366.80M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1.30B 1.27B 1.10B 925.33M 642.30M
Net Income 222.39M 263.24M 325.34M 292.47M 216.09M
EPS (Diluted) 0.05 0.06 0.07 0.06 0.05
Gross Profit 981.44M 995.64M 873.93M 747.53M 513.15M
Operating Income 186.34M 383.28M 375.93M 328.74M 264.49M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 4.90B 4.70B 3.69B 3.18B 2.95B
Total Liabilities 1.42B 1.37B 769.05M 653.61M 596.06M
Shareholders' Equity 3.49B 3.37B 2.90B 2.50B 2.34B
Total Debt 4.98M 9.30M 9.67M 15.67M 185.98M
Cash & Equivalents 665.76M 979.31M 833.79M 1.12B 971.68M
Current Assets 2.33B 2.23B 1.40B 1.84B 1.54B
Current Liabilities 815.64M 770.14M 584.74M 481.91M 493.60M

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#725 of 820
20
Value Defensive Investing (Benjamin Graham)
#136 of 708
50

Recent Activity

Entered Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entered Defensive Investing (Benjamin Graham)
Mar 24, 2026